Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Overijse – page 144

1 941 clinical trials in Overijse, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Overijse at a glance
1 941
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 941 trials in Overijse

Open in trial search

Pustular psoriasis

Not recruiting

Study on Spesolimab for Treating Recurrent Flares in Patients with Generalized Pustular Psoriasis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Chronic sinusitis

Not recruiting

Study on the Effectiveness and Safety of LYR-210 and Dexamethasone for Treating Chronic Sinusitis in Adults Without Nasal Polyps

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Lyra Therapeutics Inc.

Study of BMS-986449 and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986449-03
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Pembrolizumab with Chemotherapy for Patients with Resectable Stage II, IIIA, and IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Endometrial cancer

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Ibrutinib and Venetoclax with Chlorambucil and Obinutuzumab for First-line Treatment in Patients with Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Cerebral palsy+5

Not recruiting

Study on Valbenazine for Treating Dyskinesia in Children and Adults with Cerebral Palsy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Valbenazine Ditosylate
  • Sponsor:Neurocrine Biosciences Inc.

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Overijse

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) optimization in patients with chronic digestive conditions. This research explores various deprescribing strategies for individuals using long-term PPI therapy.

  • Functional Dyspepsia Management
  • Heartburn Treatment Optimization
  • Reflux Therapy Alternatives

The study evaluates alternative treatment approaches, including on-demand PPI use and alginate formulation therapy, compared to traditional gradual dose reduction methods.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.